Group 1 - The core focus of Ascentage Pharma is on its research and development progress, particularly the initiation of Phase I clinical trials for its BTK degrader APG-3288 targeting relapsed/refractory hematologic malignancies, with a target enrollment of 360 patients [1] - The new drug clinical application (IND) for APG-3288 was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China on February 6, 2026, marking a new phase in the global multi-center clinical development of the drug [1] - APG-3288 utilizes the PROTAC technology platform aimed at overcoming resistance issues associated with traditional BTK inhibitors, providing a new treatment option for hematologic cancers [1] Group 2 - Ascentage Pharma's stock (06855.HK) experienced slight fluctuations over the past week, closing at 47.62 HKD on February 11, 2026, with a daily increase of 0.46% and a cumulative decline of 0.38% over the past five days [2] - The stock reached a peak price of 48.60 HKD on February 9 and a low of 45.74 HKD on February 10, with a trading range of 5.98% [2] - Southbound funds increased their holdings by 59,500 shares on February 10, with a net increase of 83,000 shares over the past five days, indicating short-term capital inflow [2]
亚盛医药研发新药获临床许可，股价小幅波动